share_log

Illumina | 10-Q: Q1 2024 Earnings Report

Illumina | 10-Q: Q1 2024 Earnings Report

Illumina | 10-Q:2024财年一季报
美股SEC公告 ·  05/03 16:20

Moomoo AI 已提取核心信息

Illumina, a global leader in DNA sequencing and array-based technologies, reported a slight decrease in revenue for Q1 2024, with figures falling to $1,076 million from $1,087 million in Q1 2023. This 1% decline was primarily attributed to reduced sequencing instruments revenue, despite an increase in service and other revenue. Gross margin improved to 62.0% in Q1 2024, up from 60.3% in the previous year, driven by a favorable mix of sequencing consumables and cost-saving operational efficiencies. However, the company experienced a larger operating loss of $(111) million in Q1 2024 compared to $(64) million in Q1 2023, due to increased operating expenses, including restructuring charges. The effective tax rate for Q1 2024 was (15.3)%, a significant change from 103.9% in Q1 2023. Cash, cash equivalents, and short-term investments totaled $1,115 million at the end of Q1 2024. Illumina's business development has...Show More
Illumina, a global leader in DNA sequencing and array-based technologies, reported a slight decrease in revenue for Q1 2024, with figures falling to $1,076 million from $1,087 million in Q1 2023. This 1% decline was primarily attributed to reduced sequencing instruments revenue, despite an increase in service and other revenue. Gross margin improved to 62.0% in Q1 2024, up from 60.3% in the previous year, driven by a favorable mix of sequencing consumables and cost-saving operational efficiencies. However, the company experienced a larger operating loss of $(111) million in Q1 2024 compared to $(64) million in Q1 2023, due to increased operating expenses, including restructuring charges. The effective tax rate for Q1 2024 was (15.3)%, a significant change from 103.9% in Q1 2023. Cash, cash equivalents, and short-term investments totaled $1,115 million at the end of Q1 2024. Illumina's business development has been marked by the acquisition and planned divestiture of GRAIL, a healthcare company specializing in early cancer detection. Despite the European Commission's initial prohibition, the divestment plan was approved on April 12, 2024, with completion expected by the end of Q2 2024. Illumina operates through two segments, Core Illumina and GRAIL, with the latter being held separately due to ongoing legal proceedings. The company's future plans include a focus on cost reduction initiatives to improve margins and enable further investment in high-growth areas, while navigating macroeconomic challenges and competitive pressures, particularly in the China region.
DNA测序和芯片技术全球领导者Illumina报告称,2024财年第一季度营业收入轻微下降,数字从2023财年第一季度的1.087亿美元下降至1.076亿美元。主要归因于测序仪器收入减少,尽管服务和其他收入增加,该股收益下降了1%。毛利率提高到2024财年第一季度的62.0%,而上一年同期则为60.3%,这是由于混合使用的测序消耗品和节省成本的操作效率。然而,由于营业费用增加(包括重组费用),公司在2024财年第一季度的营业亏损达到1.11亿美元,而2023财年第一季度的亏损额为6400万美元。2024财年第一季度的有效税率为(15.3%),而2023财年第一季度为103.9%。现金、现金等价...展开全部
DNA测序和芯片技术全球领导者Illumina报告称,2024财年第一季度营业收入轻微下降,数字从2023财年第一季度的1.087亿美元下降至1.076亿美元。主要归因于测序仪器收入减少,尽管服务和其他收入增加,该股收益下降了1%。毛利率提高到2024财年第一季度的62.0%,而上一年同期则为60.3%,这是由于混合使用的测序消耗品和节省成本的操作效率。然而,由于营业费用增加(包括重组费用),公司在2024财年第一季度的营业亏损达到1.11亿美元,而2023财年第一季度的亏损额为6400万美元。2024财年第一季度的有效税率为(15.3%),而2023财年第一季度为103.9%。现金、现金等价物和短期投资截至2024财年第一季度末总计为1.115亿美元。Illumina的业务发展标志着其收购GRAIL和计划出售的行为,GRAIL是一家专注于早期癌症检测的医疗保健公司。尽管欧洲委员会最初禁止了该出售计划,但在2024年4月12日获得批准,并预计在2024年第二季度结束时完成。Illumina通过两个板块运营,即核心Illumina和GRAIL,由于正在进行的法律程序,GRAIL被单独持有。公司未来的计划包括聚焦于降低成本以提高利润率,并在高增长领域继续投资,同时在应对宏观经济挑战和竞争压力方面,特别是在中国地域板块上。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息